Drug-Tolerant Persister Cells: From Biology to Treatment

Get ready for a provocative Facebook Live session that dives into the mystery of drug-tolerant persister cells (DTPCs)—those elusive cancer cells that survive chemotherapy and targeted therapies, often fueling cancer’s return after treatment. These sneaky survivors are present in many cancers, and while scientists are uncovering their secrets, there is still much to learn about how to target them effectively.

The conversation features Jill Feldman from the EGFR Resisters and Christine Lovly, MD, PhD, Ingram Associate Professor of Cancer Research at Vanderbilt University Medical Center. Dr. Lovly, an international authority on lung cancer biology and treatment, shares her groundbreaking research on the role of drug-tolerant persister cells in EGFR-positive lung cancer—made possible by a grant from the EGFR Resisters.

This discussion is moderated by Upal Basu Roy, PhD, MPH, executive director of research at LUNGevity Foundation.